The use of semi‐compliant versus non‐compliant balloon systems for predilatation during the implantation of self‐expandable transcatheter aortic valves

Mach, Markus; Szalkiewicz, Philipp; Poschner, Thomas; Hasan, Waseem; Andreas, Martin; Winkler, Bernhard; Hašimbegović, Ena; Steinkellner, Theresia; Strouhal, Andreas; Adlbrecht, Christopher; Delle‐Karth, Georg; Grabenwöger, Martin

doi:10.1111/eci.13570

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compliance of a balloon catheter primarily depends on the increased diameter that results from a predetermined increase in inflation pressure [ 3 ]. SC balloons respond to an increase in inflation pressure and are only partially able to conquer the significant lesion resistance [ 4 , 5 ]. In contrast, NC balloons expand uniformly and typically cannot be expanded beyond a predetermined diameter limit [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Outcomes of a Non-Compliant Balloon Dilatation Catheter: MOZEC™ NC Study

Pradhan

Vishwakarma

Bhandari

et al. 2022

IJERPH

View full text Add to dashboard Cite

The present study sought to assess the clinical outcomes of the Mozec™ Non-compliant (NC) Rx PTCA balloon dilatation catheter (BDC) (Meril Life Sciences Pvt. Ltd., Vapi, India) for dilatation of coronary lesions. This was a post-marketing, single-centre, single-arm, retrospective study. In total, 57 patients who had undergone post-dilatation with the Mozec™ NC Rx PTCA balloon dilatation catheter were evaluated. The primary endpoint was procedural success defined as (i) successful delivery of the investigational device to and across the target lesion; (ii) successful inflation, deflation, and withdrawal of the investigational device; (iii) absence of vessel perforation, flow-limiting vessel dissection, increase in thrombolysis in myocardial infarction (TIMI) flow from baseline, clinically significant arrhythmia requiring medical treatment; and (iv) achievement of final TIMI flow grade 3 after percutaneous coronary intervention of the target lesion after single or multiple attempts to cross the target lesion. Procedural success was achieved in 57 (100%) patients. There were no incidences of major adverse cardiac events (MACE)/target lesion failure (TLF). Mozec™ NC Rx PTCA balloon dilatation catheter has demonstrated favourable outcomes for the dilatation of routine and complex coronary lesions in a small cohort, as evidenced by its 100% procedural success rate and absence of MACE.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In contrast, NC balloons expand uniformly and typically cannot be expanded beyond a predetermined diameter limit [ 6 ]. Thus, NC balloons provide an additional benefit of deforming in a more controlled and stable manner during inflation [ 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%